-->

Generic medicine pay-for-delay deals ‘risk breaching EU law’

Organisation: Position: Deadline Date: Location:

Pharmaceutical patent holders that enter into “pay-for-delay” agreements with generic medicine manufacturers risk breaching EU competition law on three counts, an advocate-general to the EU’s highest court has said.

According to an Out-Law.com report, pay-for-delay deals may constitute agreements that restrict competition by object, restrict competition by effect or breach rules on the abuse of a dominant market position, Juliane Kokott said this in a recent non-binding opinion, in which she considered the circumstances in which pharma patent holders and generic manufacturers can be said to be potential competitors.

Competition law expert Robert Vidal, of Pinsent Masons, said the European Commission would welcome the opinion, but said aspects of it were controversial. “Kokott believes a settlement agreement delaying generic entry can harm competition even if it turns out the generic could never compete to begin with. This does seem to dilute the objective requirement of the test for potential competition and the need to consider the counterfactual. In effect, Kokott regards patent litigation as a form of competition. It will be interesting to see what the CJEU eventually decides,” he said.

Kokott is expected to issue another opinion on similar legal issues in March following an appeal to the CJEU as a result of the European Commission’s decision to impose total fines of €146m on Lundbeck and several generic companies for entering ‘pay-for-delay’ agreements.

Full Out-Law.com report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.